Diagnostics

GE HealthCare's new FDA-cleared 'View' viewer promises to free radiologists from the workstation with a cloud-native, zero-footprint solution.

A new drug, CRS3123, not only cures C. difficile but drastically cuts recurrence rates by preserving the gut microbiome, a major leap over standard care.

At HIMSS26, Juno Health debuts its v25 EHR, leveraging AI, integrated RCM, and true interoperability to tackle clinician burnout and data silos.

An investigation into the popular SleepZee anti-snoring mouthpiece reveals a chasm between its 'clinically proven' marketing and its restrictive legal terms.

A recent scientific review links low glutathione to brain disease. A new supplement claims to solve the delivery problem. Is this the future of cognitive health?

As Hyperfine preps its 2025 results, investors and clinicians watch to see if its portable Swoop MRI can translate clinical promise into financial success.

Scientists find herpes melts the inside of our cells to replicate faster, a discovery that could revolutionize treatments for a host of viral diseases.

A new partnership integrates conversational AI with deep EHR analysis, promising to save doctors time, improve diagnoses, and boost hospital revenue.

On its 50th anniversary, NAHQ launches a new ecosystem to arm the healthcare workforce against staff shortages, financial pressures, and digital disruption.

A new partnership between Always and The Fibroid Foundation aims to break the silence on heavy periods and fibroids, combining product innovation with advocacy.

The biotech firm accelerates a key trial but faces a partner loss, widening losses, and a CEO search, putting its promising siRNA pipeline at a crossroads.

A new global survey reveals the crushing mental burden of diabetes, sparking a call for AI-powered tools that promise to restore spontaneity and control.

With strong revenue growth and critical FDA decisions on the horizon, MannKind's leadership prepares to outline its vision for investors in Miami.

As Sera Prognostics preps its year-end report, investors watch to see if its groundbreaking preterm birth test can deliver financial health.

With its lead drug for a rare blood cancer nearing European submission, Cellectar Biosciences advances its targeted radiotherapy platform on two fronts.

A massive $125M investment empowers five international teams to pursue radical ideas, from cancer-proof people to self-destructing tumors.

A nonprofit's initiative just gave its 4 millionth free vaccine, revealing a strategic model that tackles pet health crises and opens doors to lifelong care.

A new partnership integrates advanced AI for brain lesion tracking into a global imaging network, promising safer Alzheimer's treatments and faster diagnostics.

Theolytics secures a prestigious €8 million EU grant to advance its unique cancer-killing virus, offering new hope for hard-to-treat ovarian cancer.

With four new partners and a zero-markup model, Harrison.ai's Open Platform aims to democratize access to powerful medical AI tools for providers globally.